KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD

By sjmartinez • December 25, 2023

Mottl AK, Nicholas SB. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis. 2023 Dec 21:S0272-6386(23)00883-1. doi: 10.1053/j.ajkd.2023.09.003. Epub ahead of print. PMID: 38142396.

Tags: Chronic kidney disease, commentary, diabetes, evidence-based recommendation, GLP-1 RAs, guideline, guideline implementation, Nephrology, nephrology best practices, ns-MRAs, Publications, SGLT2 inhibitors

Graft Outcomes in For-Cause Biopsy-Proven Recurrent IgA Nephropathy After Kidney Transplantation: Rare but Clinically Meaningful

Inkong P, Lum EL, Kim K, Dhaliwal I, Zuckerman JE, Bunnapradist S. Graft Outcomes in For-Cause Biopsy-Proven Recurrent IgA Nephropathy After Kidney Transplantation: Rare but[...]

Development and Psychometric Evaluation of the End-Stage Renal Disease Adherence Questionnaire-Short Form: English, Spanish, and Korean Versions

Kim Y, Cho WK, Song J, Evangelista LS, Kopple JD. Development and Psychometric Evaluation of the End-Stage Renal Disease Adherence Questionnaire-Short Form: English, Spanish, and[...]

Regulatory T cell modulation with selective CD28 blockade and IL-6 receptor antagonist in kidney transplant recipients: results of CTOT-24, a prospective clinical trial

Chandran S, Tang Q, Leung JC, Armstrong BD, Friedewald JJ, Kirk AD, Laszik ZG, Goldstein J, Morsheimer M, Vincenti FG. Regulatory T cell modulation with[...]